Global Omalizumab Biosimilars Market 2026 – 2035

The global Omalizumab Biosimilars market size is projected to touch almost USD 1.65 billion by 2025 and nearly USD 1.88 billion by 2026 with an expected reach of about USD 6.20 billion by 2035, growing at a CAGR of 14.15% over the 2026-2035 forecast period. The market is registering steady growth owing to increased demand for affordable biologics for treatment of chronic allergic diseases like asthma and chronic idiopathic urticaria.

Moreover, numerous patent expirations for reference biologics and a favorable biosimilar regulatory framework, facilitating the launch of new products and market entry, are driving market growth. Further, increasing healthcare spending, enhanced access of patients to biologics and a robust pipeline of omalizumab biosimilars are anticipated to foster market growth. Increased utilization in emerging markets and various partnerships and commercialization contracts among the pharma companies are estimated to further bolster the demand for omalizumab biosimilars in the long run.

Impact of US-Iran War on the Omalizumab Biosimilars Market

The supply chain of raw materials, including cell culture media, recombinant proteins, single-use bioreactor components, chromatography resins, and sterile packaging materials required to produce omalizumab biosimilars has been impacted by the US-Iran war. Increasing crude oil prices and geopolitical instability in the Middle East have caused the increase in costs associated with petrochemical-derived plastics (e.g., tubing, filters, storage bags), purification resins, and temperature-controlled logistics, thus affecting the pricing of omalizumab biosimilars. Furthermore, disruptions to global shipping routes, particularly through the Strait of Hormuz, have delayed the delivery of critical raw materials and finished biosimilar products from manufacturing hubs in Europe, India, and China to key markets such as North America, the EU, and Asia-Pacific, impacting supply continuity and inventory management.    

Market Highlight

• The overall Omalizumab Biosimilars market in 2025 was accounted for by Asia-Pacific, contributing a 40.4% share and driven by favorable biologics adoption, well-established healthcare infrastructure, and a rise in the incidence of severe asthma and chronic spontaneous urticaria.

• By product type, Monoclonal Antibody Biosimilars occupied 42.5% share in the overall market in 2025 led by structural similarity to omalizumab, favorable clinical data and easy regulatory pathways for approval.

• The Allergic Asthma (Severe Persistent Asthma) indication occupied the leading position with a 48.5% market share in 2025 led by a patient pool of >260 million across the world and the drug's effectiveness in reducing exacerbations of allergic asthma by 14.5%.

• Atopic Dermatitis indication is expected to gain traction with the highest CAGR of 50.5% between 2026-2035, attributed to the growing incidence rate and research on IgE related pathways along with growing biologic application in the dermatology segment.

• Subcutaneous Injection administration accounted for a 53.5% share in the overall market in 2025, attributed to its convenience, application in outpatient care, and preference by chronic care management patients whereas home-based self administration is predicted to register the fastest CAGR, attributed to the patient centric care approach.

Significant Growth Factors

The Market Trends of Omalizumab Biosimilars has very serious growth potential from the below factors:

• Increasing Prevalence of Allergic & Respiratory Disorders: The rising incidences of allergic asthma, CSU & other IgE-mediated diseases are driving the growth of the omalizumab biosimilar market. Globally, asthma is affecting more than 260 million individuals, while 1% of the total world population suffers from CSU, resulting in a vast pool of potential patients. The increased rate of urbanization, changes in lifestyle, and high level of environmental pollution also contribute to higher occurrences of diseases. The ever increasing number of patients suffering from immune disorders is putting pressure for treatment with biologics like omalizumab. Since the price is very high to reach a larger group of people in developing and middle-income countries, omalizumab biosimilars can be a savior by lowering the costs.

• Patent Expiry of Xolair and Biosimilar Approvals: The patent of blockbuster drug Xolair (omalizumab) by Novartis & Genentech has ended recently, generating a significant opportunity for numerous biosimilar manufacturers to get into the market. Previously, the annual sales of this drug had crossed 4 billion USD in the global market, giving it the shape of a market worth capturing. As there are numerous candidates that can produce omalizumab, the competition is increasing in the market and consequently, the price will fall down. Regulatory agencies like the FDA, EMA and PMDA are taking initiatives for swift biosimilar approval by making their approval pathways easier. Multiple drug makers are now conducting late-stage trials for omalizumab biosimilar candidates, which are predicted to bring the drugs to the market soon and cater to a wide patient group and market both in developed and developing countries.

• Cost-Advantages and Optimizing Healthcare Budgets: Lower price of omalizumab biosimilars as compared to the reference product is one of the biggest drivers for the growth of the biosimilars market. Biosimilars generally come with a price benefit of 15-35%, giving a strong attraction for health care systems struggling with increasing spending on biologics. Almost 30-40% of drug costs are now consumed by biologics in most developed regions. In this situation, it becomes imperative for the governments and insurers to reduce this burden. The introduction of substitution policies promoting the use of biosimilars will further increase its demand. In the developed economies also the public health care systems are willing to adopt the biosimilars for affordable access to a large patient pool, and a growing reimbursement framework further fuels the demand.

• Expansion of Clinical Applications and Treatment Guidelines: Besides approved indications for moderate to severe allergic asthma and chronic spontaneous urticaria, the drug is gaining interest and clinical research is ongoing to test its efficacy on other ailments like chronic rhinosinusitis with nasal polyps, food allergies and atopic dermatitis. With a 60-70% decrease in moderate to severe asthma exacerbation and proven clinical benefits of omalizumab, its use in the clinical guidelines has begun shifting from the last line of therapy towards the initial therapy of allergic conditions. The indications of such a highly effective drug are set to grow, which also expands the target audience of omalizumab biosimilars.

• Improvements in Biomanufacturing Processes and Market Entry Strategies: Recent advancements in the field of biomanufacturing have brought down the production cost and improved production capacity for omalizumab biosimilars. Developments in cell line engineering, upstream processing and purification processes have decreased the cost and enhanced yield and quality. While the average production cost for biosimilars is generally 100-200 million USD, it is considerably less than original biologics, which has paved the way for many new pharmaceutical players to enter the market. Additionally, companies are collaborating through partnerships, joint ventures and contract manufacturing organizations for market entry. The clinical trial of biosimilars for comparison with the originator drug is also increasing physician trust which will enhance the market share of the biosimilar drugs.

What are the Significant Developments that are Powering up the Omalizumab Biosimilars Market today?

• Expanded Clinical Pipeline and Late-Stage Development Activity: One significant advancement in the omalizumab biosimilar market is the swift escalation of clinical stage candidates aimed at anti- IgE therapy. There are now more than 8-10 omalizumab biosimilar candidates globally, and many are in various stages of development in the Asian and European markets. Several firms are progressing from Phase I through III trials with an aim to exhibit bioequivalence to reference omalizumab. With the successful completion rate in monoclonal antibody biosimilars having crossed the 70% mark in late-stage programs, many firms are gaining increased confidence. This significant development of the clinical pipeline signals immense commercial expectations, as there are over 260 million asthmatics worldwide, signifying further long term market development.

• Increased Regulatory Approvals and streamlined pathways: Regulatory momentum is a driving force for the omalizumab biosimilar market, with major regulatory agencies like the EMA, FDA and the PMDA in particular, having strengthened their pathways for the approval of biosimilar drugs. There is a considerable 20-30% decrease in the timeline for obtaining approval of a biosimilar, compared to that required for earlier biologic drugs, prompting earlier market entry. Despite the emergence of omalizumab biosimilars, several monoclonal antibodies in closely related therapeutic areas have already obtained regulatory approval, paving a way for promising developments. The reduction in the need for duplicating clinical trials and emphasis on comparability further shorten development times, lower costs, and decrease development uncertainties. This increased streamlining and structured support of regulatory agencies will aid rapid approvals and promote access to affordable anti- IgE therapy.

• Technological advancements and growing manufacturing capabilities: Technological advancements in biomanufacturing have been remarkable progress for the omalizumab biosimilar market. The enhanced yields and consistent production of monoclonal antibodies have been supported by innovations such as improvements in CHO cell line performance, continuous bioprocessing techniques, and increased efficiency in purification systems. The production costs of monoclonal antibodies have been decreased by 25-40% in recent years. Global supply capability in the production of monoclonal antibodies has been increased with scale ups by Indian, South Korean and Chinese firms. Contract manufacturing organizations (CMOs) have proved beneficial in expediting the commercialization process.

• Partnerships and expanded licensing agreements: Strategic partnership has been the pivotal factor in determining the competitive landscape of the omalizumab biosimilar market. Pharmaceutical organizations are increasingly entering into licensing agreements, co-development agreements and regional distribution deals to speed up development timelines. Collaboration agreements for biosimilars, in particular, among biosimilar focused companies have increased by 30% over the last few years. These partnerships have allowed smaller biotech firms to access manufacturing capabilities and regulatory expertise while enabling large pharmaceutical players to widen their portfolio. Collaborations between large pharmaceutical companies in developed regions and Asian contract manufacturers are witnessing high activity as they seek cost-effectiveness and market access in regions where there is significant demand for asthma therapy.

Category Wise Insights

By Product Type

Why Monoclonal antibody biosimilars Leads the Market?

Monoclonal antibody biosimilars hold a prominent position in the Omalizumab biosimilar market owing to their highly homologous nature. This structural similarity to omalizumab, which is a recombinant monoclonal antibody designed to inhibit IgE-mediated allergic reactions, guarantees considerable clinical acceptance, predictable responses, and consistent treatment outcomes for both asthma and CSU patients. Over 60% of total biosimilar pipelines worldwide include monoclonal antibody biosimilars, thereby reflecting an intensified interest from the pharmaceutical industry, more robust regulatory pathways, quicker regulatory approvals, and superior acceptance rates by healthcare professionals, in addition to providing clinical confidence and interchangeability with the reference product.

The fastest growing sub-segment in the product type classification, the long-acting biosimilar formulation addresses patient needs and convenience with improved treatment schedules. Traditional omalizumab requires injections every 2-4 weeks, which may be challenging for patients suffering from chronic conditions such as Asthma and CSU to administer injections regularly, leading to low treatment adherence. Long-acting biologics are expected to decrease the frequency of subcutaneous injections while ensuring optimal therapeutic efficacy.

Evidence-based clinical studies on biologics claim that a more extended injection schedule can lead to about 15-25% improvement in adherence, thereby boosting treatment outcomes, consequently encouraging higher investment towards the development of sustained-release biologic technologies. Although the segment is still in the early stages of development, there is a tremendous expectation that sustained-release biosimilar formulation will grow at a rapid pace with advanced next-generation biologics and delivery systems.

By Indication

Why Allergic Asthma Leads the Market?

Severe persistent allergic asthma constitutes the largest and the fastest growing indication of the Omalizumab biosimilar market due to a larger patient population requiring biologic intervention and the need to cater to an increasing unmet need. Asthma patients around the world number over 260 million, of which a major portion requires biologics due to their intolerance towards conventional inhaled treatment. Clinical trial data suggests that omalizumab can induce a 60-70% reduction in severe exacerbations, thereby positioning it as an effective add-on therapy for poorly controlled Asthma. It being a chronic condition, it requires long-term treatment with biologics that drives the overall demand for drugs in this category, further reinforcing the indication as the largest in terms of revenues generated.

Atopic Dermatitis holds the second largest and also the fastest growing indication in the market owing to its rapidly increasing prevalence worldwide coupled with growing recognition of its IgE-mediated inflammatory nature. Around 10-20% of children and 1-3% of the global adult population suffers from Atopic Dermatitis, which is even higher in urban areas. Severe Atopic Dermatitis patients typically show limited response to conventional treatments leading to the requirement of biologics to control the disease progression and associated inflammation. Omalizumab is not yet predominantly approved as an indication of choice for Atopic Dermatitis, however, early stages of clinical trials prove promising. Strong pipeline research and increasing adoption of biologics for dermatological applications, especially Atopic Dermatitis, drives rapid market growth for Atopic Dermatitis indications. Regulatory approvals for the treatment of Atopic Dermatitis is also expected to rise, further strengthening market share in the coming years.

By Route of Administration

Why Subcutaneous injection Leads the Market?

Subcutaneous injections currently dominate the Omalizumab biosimilar market based on several key factors of convenience, suitability for long-term treatment and well-established usage. In most of the allergic and immunological diseases, biologics are typically administered every 2-4 weeks which makes subcutaneous injections a much more convenient mode of administration for chronic use and outpatient settings.

The vast majority (>90%) of allergy and immunology biologics is administered via subcutaneous injections in the United States of America and in most other developed nations. This eliminates reliance on clinical settings, enables home administration and helps ensure optimal treatment adherence among patients. Therefore, subcutaneous injections become the primary method of administration for patients.

Home-based administration of subcutaneous omalizumab biosimilars is the fastest growing trend under route of administration classification. It fulfills patients’ desires for greater ease of administration, avoiding the burden of traveling to medical facilities and enabling decreased healthcare costs. Patients administered home-based biologic therapies were shown to have an adherence of about 20-30% greater than hospital-administered therapy in some biologics, thereby minimizing clinician burden.

Furthermore, patients gain independence of self-administration through readily available digital health monitoring systems and comprehensive patient training programs. Healthcare organizations increasingly advocate for distributed care models, particularly in the wake of the COVID-19 pandemic. With increasingly competitive biosimilar prices and ease of administration for future biologics, home-based delivery systems are set to bloom in the foreseeable future, especially in developing countries equipped with robust healthcare infrastructure enabling home-based self-care.

Report Scope

Regional Analysis

What is the Size of Asia Pacific Market?

The Asia Pacific Omalizumab Biosimilars market is anticipated to reach USD 0.62 billion in 2025 and is expected to reach approximately USD 2.49 billion by 2035 with a 14.92% CAGR from 2026 to 2035.

Why will Asia Pacific Dominate the Market in 2025?

Asia Pacific is expected to dominate the omalizumab biosimilars market because of the large patient population, the increasing prevalence of allergic asthma, and a well-established biosimilar manufacturing infrastructure. Together, countries such as China, India, Japan, and South Korea represent a large portion of global asthma cases; asthma prevalence is as high as 8-12% in urban segments of some populations. Furthermore, the APAC region provides cost benefits—up to 30-40% less than Western markets—for biologics production and government support for biosimilars. Increased access to healthcare, improvement in hospital infrastructure, and subsequent approvals are reinforcing its leading market position.

China Market Trends

China is the growth driver for the omalizumab biosimilar market due to a quickly growing biologics industry and high respiratory disease burden. Asthma affects more than 45-50 million people in China, thereby creating a high demand for advanced therapies. China's 'Healthy China 2030' initiative is further promoting the use of biosimilars and the development of domestic biologics. Biopharmaceutical firms in China are making investments in the development of monoclonal antibody biosimilars, aided by quick regulatory approvals from the NMPA. In addition, growing spending on healthcare facilities and well-developed hospital networks have accelerated adoption making China a major market in the Asia Pacific region.

What is the Reason behind the steady Growth in North America?

The steady growth of the North America market for omalizumab biosimilars can be attributed to high healthcare expenditure, the advanced adoption of biologics, and strong regulatory frameworks. The U.S. Market alone contributes almost 40-45% to the overall global biologics market consumption, providing stable demand. An increasing prevalence of chronic urticaria and severe asthma affects 25+ million patients with asthma across the U.S., further stimulating biologics usage. The existence of leading pharmaceutical companies and robust biosimilar pipelines is a support for innovation. The market growth, however, is slightly tempered by a slower penetration of biosimilars due to the reluctance of doctors and established brand preferences.

U.S. Market Trends

The US market is powered by growing adoption of biologics for severe asthma and chronic spontaneous urticaria. Omalizumab is widely used by specialist clinics and studies prove a 70% reduction in asthma exacerbations. The FDA's biosimilar approval process is promoting pipeline development and several monoclonal antibody biosimilars are in late-stage development. However, market penetration remains slow due to the physicians’ preference for originators. Payer pressure on biologic costs and expanding real-world evidence supporting biosimilars will boost the adoption over the coming years.

What is the Reason behind Europe Implementing Sustainability and Efficiency?

Europe represents the large omalizumab biosimilar market due to well-developed healthcare systems and proactive biosimilar adoption policies. European countries such as Germany, France, and the UK are highly incentivized to promote biosimilars due to the rising costs of biologics which comprise 30% of total expenditure on pharmaceuticals in some European systems. High prevalence of asthma and growing, aged populations are also fueling the demand for the drug. Approval process is accelerated by regulators such as the EMA streamlining biosimilar development. With its strong emphasis on sustainable healthcare, Europe is one of the most developed biosimilar markets.

Germany Market Trends

Germany is one of the foremost European markets for omalizumab biosimilars due to the strong healthcare infrastructure and quick biosimilar adoption. 5-7% of the population of Germany suffers from asthma, thereby ensuring a constant patient pool. The market holds one of the highest rates of biosimilar acceptance rates across Europe due to awareness among the doctors and incentives for reimbursements. The well-established German pharmaceutical manufacturing and R&D base further strengthened the position of the country. Hospital procurement is aggressively pushing cost-efficient drugs, resulting in the increased use of biosimilars as one of the vital tools in its healthcare cost management strategy.

What is the Reason why the Middle East & Africa Region is Growing?

The MEA region exhibits steady market growth due to increasing health investments and soaring awareness of the advancement of biologic therapy. Prevalence of asthma in urban regions in the MEA region lies between 10-15% and is especially higher in the Gulf nations. Government support for improved healthcare and provision for specialty medications in nations like UAE, Saudi Arabia and South Africa is escalating. High costs of biologics are limiting the usage of the drugs; thus, biosimilars are considered a valuable alternative. Increased collaboration with global pharmaceutical firms and growing hospital development are paving the path for market growth and positioning MEA as an emerging opportunity in the future.

Top Players in the Market and Their Offerings

• Novartis AG

• Genentech (Roche Group)

• F. Hoffmann-La Roche Ltd

• Teva Pharmaceutical Industries Ltd

• Sandoz Group AG

• Amgen Inc.

• Celltrion Inc.

• Samsung Bioepis Co. Ltd.

• Biocon Biologics Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Biogen Inc.

• Pfizer Inc.

• Merck & Co. Inc.

• AbbVie Inc.

• Amneal Pharmaceuticals LLC

• Fresenius Kabi AG

• STADA Arzneimittel AG

• Alvotech

• Lupin Limited

• Intas Pharmaceuticals Ltd.

• Others

Key Developments

The market has evolved a lot within the industry, with players trying to increase their activities and product portfolios.

• ·January 2025 saw the leading biosimilar producer, Celltrion Inc. Grow its monoclonal antibody pipeline, as it launched late-stage development programs for anti-IgE and allergy biosimilars to bolster its respiratory biologics pipeline.

• By March 2025 Samsung Bioepis stated it would be progressing its immunology biosimilar pipeline, concentrating its efforts on high-complexity monoclonal antibodies, including IgE-targeting agents so that the accessible use of affordable biologics might be increased worldwide.

These are strategic efforts enabling players to strengthen their market positions and increase product innovation while taking advantage of a general move towards minimally invasive, disposable surgical solutions in worldwide markets.

The Omalizumab Biosimilars Market is segmented as follows:

By Product Type

• Monoclonal Antibody Biosimilars

• Recombinant Anti-IgE Biosimilars

• Long-acting Biosimilar Formulations

By Indication

• Allergic Asthma

• Chronic Spontaneous Urticaria (CSU)

• Allergic Rhinitis

• Nasal Polyps

• Atopic Dermatitis

• Other

By Route of Administration

• Subcutaneous Injection

• Intravenous

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America